How long does retatrutide take to work? The published onset data. | Reddit

The precise version of the question has no published answer: no trial reports the day or week at which an individual participant first noticed anything. What the record offers instead is a series of fixed measurement points, and the honest way to answer “how long to work” is to line those up from earliest to latest and say what each one showed.

Day 43, from a single injection. The discovery-to-clinic report in Cell Metabolism states that in the phase 1 single-ascending-dose study a reduction in body weight persisted up to day 43 after a single dose. That is an unusually long tail for one injection, and it is consistent with the approximately 6-day half-life reported in the phase 1b trial.

The first multi-week efficacy readout came at 12 weeks: the phase 1b trial in people with type 2 diabetes reported placebo-adjusted bodyweight reduction of up to 8.96 kg in the group that escalated through 3, 6, 9 and 12 mg. Both findings are early-phase data in small cohorts, which is exactly what phase 1 exists to produce, and neither is an approved-use result.

Two clocks run slowly at the start, by design. The first is titration: the phase 2 obesity trial assigned initial doses of 2 mg or 4 mg against final targets of up to 12 mg, and its abstract notes that gastrointestinal adverse events were partially mitigated with a lower starting dose (2 mg vs. 4 mg). A participant in week 3 was on a fraction of the dose the headline numbers were produced at.

The second is accumulation. At the approximately 6-day half-life, weekly injections take roughly 4 to 5 half-lives, about 4 to 5 weeks, to reach steady state per the standard rule in StatPearls. The full arithmetic lives in our retatrutide half-life article. Layer the two clocks and the published design expects little in month one, which is worth knowing before reading any 48-week figure.

Week 24 is the first point where the phase 2 program published arm-by-arm numbers, and it is the most defensible “it was clearly working by now” marker in the record.

Appetite is usually the first thing forum posts describe, and it is also the place where the published record is thinnest on timing. The dedicated appetite analysis, a 2025 report in Diabetes, Obesity & Metabolism covering 275 adults with type 2 diabetes, measured appetite and eating-behaviour scores at 24 and 36 weeks. Nothing earlier is reported in that abstract, so any claim about appetite changing in week one or week two of a trial is not sourced from the published record.

The earliest liver readout is 24 weeks, the primary endpoint of the phase 2a substudy in Nature Medicine, run in 98 participants with metabolic dysfunction-associated steatotic liver disease and at least 10% liver fat.

No. Half-life describes how fast the drug leaves, not how fast effects arrive. Concentration builds across the first 4 to 5 weeks of weekly dosing before it plateaus, and the trials were still titrating upward through that window. The two published early signals, day 43 after a single dose and 8.96 kg placebo-adjusted at week 12, are the floor and the first checkpoint of the published onset picture, not a promise about any individual week.

Because the headline figures, 22.8% on 8 mg and 24.2% on 12 mg, come from the 48-week phase 2 obesity readout, and social posts routinely quote them without the timescale. The same arms stood at 17.3% and 17.5% at week 24, so roughly a quarter of the 48-week result accrued in the second 24 weeks. Reading a 48-week mean as a 12-week expectation is the most common misquote in retatrutide content. The week-by-week arc across every published study is laid out in our retatrutide timeline article.

Circulating videos tend to be more careful about onset than about sourcing. A widely shared dose-ladder video claims doses step up at 4-week intervals, which would put a viewer months from any full dose; the published abstracts confirm escalation existed but do not state the calendar. Another circulating claim, that liver fat can fall dramatically within months, matches the direction of the published 24-week substudy data. The pattern to keep: check each claim against a trial timepoint, and treat anything without one as a creator claim.

The gaps are as quotable as the numbers, because they mark where every confident-sounding answer stops being sourced.

If the underlying goal is metabolic and weight management support, there are therapies a licensed clinician can prescribe today and a licensed US pharmacy can prepare today. Semaglutide and tirzepatide both have approved products behind them and an established prescribing route, and a clinician decides whether either is appropriate for your history.

Every dose PepScribe dispenses is compounded in the USA by licensed 503A pharmacies. No hidden overseas supply chain. The online visit is free, and you pay only if a clinician prescribes.